IL-2 induces T cell adherence to extracellular matrix: inhibition of adherence and migration by IL-2 peptides generated by leukocyte elastase.
Migration of inflammatory cells requires cell adhesion and their subsequent detachment from the extracellular matrix (ECM). Leukocyte activation and migration must be terminated to stop inflammation. Here, we report that IL-2 enhances human T cell adherence to laminin, collagen type IV, and fibronectin (FN). In contrast, neutrophil elastase, an enzyme activated during inflammation, degrades IL-2 to yield IL-2 fractions that inhibit IL-2-induced T cell adhesion to FN. The amino acid composition of two of these IL-2 fractions, which appear to block T cell adherence to FN, were analyzed, and three peptides were consequently synthesized. The three peptides IVL, RMLT, and EFLNRWIT, but not the corresponding inversely synthesized peptides, inhibited T cell adhesion to FN induced by a variety of activators: IL-2, IL-7, macrophage inflammatory protein (MIP)-1beta, and PMA, as well as anti-CD3 and anti-beta1 integrin-activating mAb. Moreover, these IL-2 peptides inhibited T cell chemotaxis via FN-coated membranes induced by IL-2 and MIP-1beta. Inhibition of T cell adherence and migration apparently involves abrogation of the rearrangement of the T cell actin cytoskeleton. Thus, the migrating immune cells, the cytokines, and the ECM can create a functional relationship in which both inflammation-inducing signals and inhibitory molecules of immune responses can coexist; the enzymatic products of IL-2 may serve as natural feedback inhibitors of inflammation.
Ariel
A
A
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Yavin
E J
EJ
Hershkoviz
R
R
Avron
A
A
Franitza
S
S
Hardan
I
I
Cahalon
L
L
Fridkin
M
M
Lider
O
O
D000199:Actins / Q000037:antagonists & inhibitors / Q000502:physiology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000918:Antibody Specificity; D002448:Cell Adhesion / Q000187:drug effects / Q000276:immunology; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology*; D054407:Chemokine CCL4; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003094:Collagen / Q000187:drug effects / Q000378:metabolism; D003599:Cytoskeleton / Q000187:drug effects / Q000502:physiology; D005109:Extracellular Matrix / Q000187:drug effects / Q000276:immunology* / Q000502:physiology; D005353:Fibronectins / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D007376:Interleukin-2 / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D007797:Laminin / Q000187:drug effects / Q000378:metabolism; D019272:Leukocyte Elastase / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000187:drug effects; D019402:Macrophage Inflammatory Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*
D000199:Actins; D000911:Antibodies, Monoclonal; D054407:Chemokine CCL4; D005353:Fibronectins; D007376:Interleukin-2; D007797:Laminin; D019402:Macrophage Inflammatory Proteins; D010446:Peptide Fragments; D003094:Collagen; D019272:Leukocyte Elastase